Kainos Medicine KRX:284620KOSDAQ
카이노스메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Kainos Medicine reported revenue of ₩408m, up 131.2% year on year, and an operating loss of ₩1.1bn. Kainos Medicine (카이노스메드) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 21 with 1 article. The most common catalyst was tech & capacity (1). It was most often mentioned alongside KM.
Filing signals 4 quarters of losses Screener
Kainos Medicine quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩408m | +131.2% | −₩1.1bn margin −258.1% | −₩1.3bn |
| Q1 2026 | ₩370m | +0.4% | −₩1.0bn margin −273.2% | −₩1.3bn |
| Q4 2025 derived | ₩304m | +326.3% | −₩2.3bn | −₩1.9bn |
| Q3 2025 | ₩322m | +58.2% | −₩1.5bn | −₩1.8bn |
| Q2 2025 | ₩176m | -0.1% | −₩945m | −₩1.9bn |
| Q1 2025 | ₩369m | +165.9% | −₩1.7bn | −₩2.2bn |
| Q4 2024 derived | ₩71m | -29.4% | −₩4.2bn | −₩4.2bn |
| Q3 2024 | ₩204m | +302.7% | −₩2.4bn | −₩2.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kainos Medicine top stories 2 weeks, by number of outlets
- 1